Vaccines against human papillomavirus.

@article{Lin2007VaccinesAH,
  title={Vaccines against human papillomavirus.},
  author={Yen-Yu Lin and Hannah H. Alphs and Chien-Fu Hung and Richard B. S. Roden and T.-C. Wu},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2007},
  volume={12},
  pages={
          246-64
        }
}
Human papillomavirus has been identified as an etiological factor for cervical cancer, anogenital cancers and a subset of head and neck cancers. These important observations suggest that HPV vaccines have potential in the prevention and treatment of cervical cancer and other HPV-associated malignancies. The HPV genome encodes two HPV late genes, L1 and L2, which form the viral capsid. Early viral proteins support viral genome replication, two of which (E6 and E7) are important for HPV… 
View on PubMed
bioscience.org
27 Citations
Highly Influential Citations
1
Background Citations
7

Tables from this paper

27 Citations

Citation Type

Citation Type

Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins.
A prime/boost strategy by DNA/fowlpox recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated cancers.
A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil®)
  • V. A. Govan
  • Biology, Medicine
    Therapeutics and clinical risk management
  • 2008
TLDR
Data from the Phase III trial demonstrated that Gardasil was 100% effi cacious in preventing precancerous lesions of the cervix, vulva, and vagina and effective against genital warts and it is expected to reduce the incidence of these type specifi c HPV-induced diseases in the future.
Human Papillomavirus Vaccines
TLDR
Sexual abstinence is the most effective preventive measure against HPV infection and other sexually transmitted diseases (STDs) and successful strategies that can protect against HPV infections are expected to decrease the rates of HPV-related diseases.
Human papillomavirus infection, cancer & therapy.
TLDR
The functions of the viral proteins that appear to be the most appropriate for the development of therapeutics aimed at the treatment of viral infection and virus-induced cancers are discussed.
Treatment, Follow-up, and Prevention of Papillomavirus Infection and Cervical Cancer
TLDR
Over a period of 6 months, cross-protection was observed against persistent infections with HPV-45, HPV-31, and HPV-52, and at 12 months, modest protection was demonstrated against persistence with 12 combined oncogenic HPV types.
Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
TLDR
Prophylactic HPV vaccines safely and effectively prevent HPV infection and precancerous lesions in the cervix and create new clinical opportunities for community pharmacists, provided needed legal, regulatory, and policy changes are made.
Immunotherapeutic polyoma and human papilloma virus-like particles.
TLDR
These VLPs can induce B- or T-cell immune responses and be used as preventive or therapeutic vaccines against cancers induced by the corresponding virus, or a cancer bearing the selected tumor antigen.
Vaccines for human papillomavirus infection: a critical analysis.
TLDR
A critical look at the pros and cons of human papillomavirus (HPV) vaccines.
cell cycle check point control and genomic instability allowing accumulation of damaged genes and facilitating the evolution of invasive cancer
TLDR
The background to and progress in vaccine development and the issues surrounding the introduction of HPV vaccines are discussed, although vaccines targeting the conserved regions of the L2 minor capsid protein warrant further exploration.
...
1
2
3
...

References

SHOWING 1-10 OF 182 REFERENCES
Human papillomavirus vaccines for the prevention and treatment of cervical cancer.
TLDR
If these prophylactic and therapeutic HPV vaccines prove as successful in patients as they have in animal models, HPV vaccines may have a role in the control of HPV infection and HPV-associated disease.
HPV DNA vaccines.
TLDR
Various strategies to enhance preventive and therapeutic effects of DNA vaccines are currently under active investigation and should they fulfill their promise, these DNA vaccines may prevent HPV infection or control HPV-related cervical lesions.
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.
TLDR
High-risk genotypes of the human papillomavirus (HPV), particularly HPV type 16, are found in a distinct subset of head and neck squamous cell carcinomas (HNSCC) and may be prevented or treated by vaccines designed to induce appropriate HPV virus-specific immune responses.
Vaccines against human papillomavirus and cervical cancer: promises and challenges.
A review of human papillomavirus vaccines: from basic science to clinical trials.
  • J. Berry, J. Palefsky
  • Biology, Medicine
    Frontiers in bioscience : a journal and virtual library
  • 2003
TLDR
Therapeutic vaccine trials are reviewed including E6 and E7 vaccines comprised of peptides, fusion proteins, encapsulated plasmid DNA, and recombinant vaccinia virus, which appear to be safe, well tolerated, and preliminary data indicates that most are clinically effective.
Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
  • A. Kaufmann, P. Stern, +16 authors H. Zwierzina
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
This study confirmed the safety and immunogenicity of the vaccine in a proportion of those patients vaccinated with TA-HPV, a live recombinant vaccinia virus expressing modified forms of the HPV-16 and -18 E6 and E7 proteins.
HPV protein/peptide vaccines: from animal models to clinical trials.
TLDR
The development of such a vaccine would ultimately result in a reduction in the incidence of cervical cancer and some other HPV-linked cancers and may provide therapy for individuals harboring papillomavirus lesions.
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
TLDR
The HPV-16 L1 vaccine induces not only robust B cell responses but also L1-specific T cell responses detectable by proliferation of both CD4+ and CD8+ T cells and in vitro production of both Th1- and Th2-type cytokines.
A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
...
1
2
3
4
5
...